Formulary Amendments |
Last updated: 21st October 2024 |
Chapter |
Change |
Traffic light status |
Reason for change |
01.05.03 |
Risankizumab for treating moderately to severely active ulcerative colitis |
|
NICE TA998 |
02.05.01 |
Sildenafil - amendment of secondary Raynaud's to Raynaud's |
|
NENC Medicines Committee (August 2024) |
02.10.02 |
Tenecteplase for treating acute ischaemic stroke |
|
NICE TA990 |
03.09.01 |
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) |
|
NICE TA969 |
04.01.01 |
Daridorexant - addition of NHCFT to list of providers |
|
NENC Medicines Committee (August 2024) |
04.03.03 |
Fluoxetine 10mg capsules - addition of formulation |
|
NENC Medicines Committee (August 2024) |
04.06 |
Doxylamine & pyrodoxine for use in nausea and vomiting in pregnancy |
|
NENC Medicines Committee (August 2024) |
04.07.02 |
Morphine sulfate oro-dispersible tablets (Actimorph) added and Sevredol removed |
|
NENC Medicines Committee (August 2024) |
04.07.04.02 |
Atogepant for preventing migraine |
|
NICE TA973 |
05 |
Addition of link for cellulitis diagnosis and management |
|
NENC Medicines Committee (August 2024) |
05.03.01 |
Addition of bictegravir, emtricitabine, tenofovir alafenamide (Biktarvy®) |
|
Correction of missing entry |
06.03.02 |
Hydrocortisone oral solution & merged entries |
|
NENC Medicines Committee (August 2024) |
06.04.01.02 |
Progesterone - Addition of Utrogestran vaginal capsules and clarification of use in relation to NICE NG25 |
|
NENC Medicines Committee (August 2024) |
06.07 |
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome |
|
NICE HST31 |
07.04.02 |
Vibegron for treating symptoms of overactive bladder syndrome |
|
NICE TA999 |
08.01.05 |
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma |
|
NICE TA964 |
08.01.05 |
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over |
|
NICE TA977 |
08.01.05 |
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency |
|
NICE TA963 |
08.01.05 |
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) |
|
NICE TA968 |
08.01.05 |
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over |
|
NICE TA967 |
08.01.05 |
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) |
|
NICE TA966 |
08.01.05 |
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma |
|
NICE TA974 |
08.01.05 |
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) |
|
NICE TA976 |
08.01.05 |
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) |
|
NICE TA978 |
08.02.02 |
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) |
|
NICE TA972 |
09.01.01.01 |
Addition of position statement for oral iron supplementation for iron deficiency anaemia |
|
NENC Medicines Committee (August 2024) |
10.02.02 |
Quinine Sulfate - addition of 200mg tablets |
|
NENC Medicines Committee (August 2024) |
11.04.01 |
Hydroortisone Sodium Phosphate eye drops for patients who require a preservative-free low potency ocular corticosteroid |
|
NENC Medicines Committee (August 2024) |
13.05.03 |
Pimecrolimus cream - additional wording to clarify initiation |
|
NENC Medicines Committee (August 2024) |
13.05.03 |
Tacrolimus ointment - additional wording to clarify initiation |
|
NENC Medicines Committee (August 2024) |
15.01.01 |
Ketamine in palliative care - changed from Amber to Red |
|
NENC Medicines Committee (August 2024) |